Supplier Concentration Risk Mitigation for Indian Corporates: 2026 Metrics, Insurance, and Strategy

The 2020 to 2026 period reset the Indian corporate view on supplier concentration. The COVID-19 supply chain disruption demonstrated that the assumed availability of suppliers, logistics, and inputs was not a given. The semiconductor shortage through 2021 to 2023 demonstrated that single-source dependencies on specific component categories could halt production for months. The active pharmaceutical ingredient (API) import-dependency exposure exposed by the China lockdowns in 2022 demonstrated that the Indian pharmaceutical industry's input-chain concentration was a strategic vulnerability. The 2024 to 2025 Red Sea shipping disruption and the ongoing geopolitical risks on specific trade routes have reinforced the lesson: supplier concentration is no longer a procurement efficiency consideration; it is a primary corporate risk requiring board-level attention.

The regulatory environment has responded to the shift. The Production Linked Incentive (PLI) schemes across multiple sectors have specific objectives around supply chain de-risking and import substitution. The Companies Act 2013 framework through Section 134(3)(n) and Section 177(4)(vii) places risk management obligations that necessarily address supplier concentration as one of the material risks. The SEBI Business Responsibility and Sustainability Reporting (BRSR) framework requires disclosure of supplier diversity and concentration metrics. The Ind AS 109 requires recognition of expected credit losses on receivables which extends to supplier counterparty exposure. The combined framework drives Indian corporates toward structured supplier concentration risk management.

The insurance market response has also moved. Contingent business interruption (CBI) cover has expanded materially through 2023 to 2026 with named-supplier and unnamed-supplier extensions becoming standard placement components on property programmes for supplier-concentrated buyers. Supply chain insurance as a distinct product category has grown with Indian and international capacity providers offering covers responding to supplier disruption beyond the property-loss-trigger requirement. Trade credit insurance on supplier prepayment and customer credit exposure has expanded with multiple Indian insurers and international capacity active in the market.

The 2026 Indian corporate position on supplier concentration risk is therefore materially different from the 2020 baseline. The risk is measured systematically with structured metrics, monitored continuously through supplier financial-health intelligence, mitigated through dual-sourcing and pre-positioned alternates, transferred where appropriate through CBI and supply chain insurance, and reported through board-level governance.

This guide lays out the 2026 framework for supplier concentration risk mitigation. It covers measurement metrics (Herfindahl index, top-3 dependency), CBI cover design (named-supplier and unnamed-supplier structures, limits and deductibles), supplier financial-health monitoring, dual-sourcing economics, the semiconductor and API import-dependency exposures, and the post-COVID supplier audit framework. It is written for chief procurement officers, chief risk officers, chief financial officers, and the broker advisors supporting them on insurance and supply chain programme design.

Supplier concentration risk requires structured measurement before mitigation strategies can be designed. The 2026 measurement framework uses three complementary metrics, each capturing a different aspect of the concentration pattern.

The Herfindahl-Hirschman Index (HHI)

The Herfindahl-Hirschman Index is a measure of concentration calculated as the sum of squared supplier shares (each supplier's share of total spend or volume in the relevant category, squared and summed across all suppliers). The HHI ranges from close to zero (perfectly diversified supplier base) to 10,000 (single-supplier monopoly).

A practical interpretation framework for Indian corporate supplier categories uses the following thresholds.

1. HHI below 1,500: low concentration. The supplier base is diversified and individual supplier disruption is unlikely to affect the company materially.
2. HHI 1,500 to 2,500: moderate concentration. Specific supplier disruption could affect operations, particularly during demand spikes.
3. HHI 2,500 to 5,000: high concentration. Supplier disruption is likely to produce material operational impact.
4. HHI above 5,000: very high concentration. Single-supplier disruption can halt operations in the relevant category.

The HHI should be calculated by category (raw materials, components, packaging, services, logistics) rather than aggregated across the supplier base. Category-level HHI reveals concentration patterns that aggregate metrics mask. A company with low aggregate HHI may have high HHI in specific critical categories.

Top-3 dependency

The top-3 dependency metric measures the share of total category spend or volume from the three largest suppliers. The metric is simpler than HHI and easier to communicate at board level. The interpretation framework uses the following thresholds.

1. Top-3 below 40 percent: diversified.
2. Top-3 40 to 60 percent: moderate concentration.
3. Top-3 60 to 80 percent: high concentration.
4. Top-3 above 80 percent: very high concentration.

The top-3 metric should be calculated alongside HHI for the same categories, with both metrics providing the basis for the concentration discussion.

Single-source identification

Single-source identification is the binary classification of supplier dependencies as either single-source or multi-source. A single-source dependency is a category where the company has only one qualified supplier capable of meeting the technical, quality, and capacity requirements. The single-source status may exist for technical reasons (intellectual property restrictions, qualification barriers), operational reasons (capacity scale requirements), or historical reasons (single supplier relationship not actively diversified).

The single-source inventory should be maintained as a distinct list, with each single-source dependency carrying specific risk treatment including monitoring, alternate-source qualification plans, and insurance treatment.

Sub-tier supplier concentration

Supplier concentration at the direct (tier-1) level may be diversified while sub-tier (tier-2, tier-3) concentration remains concentrated. The pattern is common in electronics, automotive, and pharmaceuticals where multiple tier-1 suppliers may all depend on the same tier-2 or tier-3 source. The 2026 measurement practice for high-concentration sectors increasingly extends to sub-tier mapping, with the company's tier-1 suppliers providing supplier-of-supplier visibility for the highest-criticality categories.

The sub-tier visibility is difficult to obtain in many cases because tier-1 suppliers treat their sub-tier sourcing as commercially confidential. The 2026 practice typically uses negotiated visibility agreements with the most important tier-1 suppliers and sample-based visibility for the broader supplier base.

Geographic and political concentration

Geographic concentration is the share of supplier base or volume sourced from specific geographic origins. The political risk dimension is the share sourced from countries or regions with elevated geopolitical risk that could affect supply continuity.

For Indian corporates the dominant geographic concentration pattern is China sourcing across multiple categories. The 2026 strategic objective of the China-plus-one transition involves systematic reduction of China concentration in selected categories, with the measurement framework tracking progress on the China share by category.

Contingent business interruption (CBI) is the primary insurance response to supplier concentration risk. CBI responds when financial loss to the insured arises from damage at a supplier's location (rather than at the insured's own location). The cover is the structural counterpart to the buyer's own BI cover, extending the BI logic upstream into the supply chain.

Named-supplier extensions

Named-supplier CBI extensions cover identified specific suppliers listed in the policy schedule. The cover responds when damage at the named supplier's location causes a disruption affecting the insured. The named-supplier approach provides the strongest cover position because the supplier is specifically agreed to be within scope.

Named-supplier extensions typically operate with the following structure.

1. Specific named suppliers identified in the policy schedule with their location addresses and the nature of their supply.
2. Per-supplier sub-limit capping the indemnity from any single named supplier's disruption.
3. Aggregate limit capping total named-supplier indemnity in the policy year.
4. Time-element deductible before indemnity commences, typically 7 to 21 days for major named suppliers.
5. Indemnity period defining the maximum claim duration, typically 6 to 24 months.
6. Covered perils at the supplier location, typically aligned with the buyer's own policy perils (fire, special perils, monsoon flood, cyclone, machinery breakdown for industrial suppliers).

The placement of named-supplier extensions requires supplier identification at placement and the supplier's location and operations to be acceptable to the insurer. Insurers may decline named-supplier extensions for suppliers in particularly high-risk locations or for suppliers with poor risk management evidence.

Unnamed-supplier extensions

Unnamed-supplier CBI extensions cover the supplier base generally without specific supplier identification. The cover responds when damage at any supplier's location (within defined criteria) causes a disruption affecting the insured. The unnamed-supplier approach provides broader cover at reduced limits.

Unnamed-supplier extensions typically operate with the following structure.

1. Defined supplier criteria specifying which suppliers fall within scope (typically suppliers exceeding defined volume or value thresholds, or suppliers within specified categories).
2. Per-supplier sub-limit typically lower than named-supplier sub-limits.
3. Aggregate limit for unnamed-supplier indemnity in the policy year.
4. Time-element deductible typically longer than named-supplier deductibles.
5. Covered perils typically aligned with the buyer's policy.
6. Geographic limitations sometimes restricting cover to specific countries or excluding the highest-risk geographies.

Limits and pricing

CBI limits for Indian corporates in 2026 vary widely by buyer size, sector, and concentration profile. Typical placement bands include the following.

1. Mid-market manufacturers with moderate concentration: named-supplier sub-limits of INR 15 to 75 crore per supplier, aggregate of INR 100 to 250 crore.
2. Large-cap manufacturers with high concentration: named-supplier sub-limits of INR 75 to 300 crore per supplier, aggregate of INR 300 to 800 crore.
3. High-dependency sectors (automotive OEMs, electronics, pharma): named-supplier sub-limits above INR 300 crore for the most critical suppliers, aggregate above INR 1,000 crore.
4. Unnamed-supplier coverage: per-supplier sub-limits typically 25 to 50 percent of named-supplier sub-limits, aggregate typically 50 to 75 percent of total CBI aggregate.

Pricing for CBI in 2026 typically runs at 1.2 to 4 percent of CBI limit annually, scaled to the supplier risk profile, the geographic concentration, the time-element deductible, and the buyer's own risk management evidence.

Cover triggers and the property-damage requirement

Standard CBI cover requires physical damage at the supplier's location as the trigger. The damage must be of a type that would have been covered under the buyer's own property policy if it had occurred at the buyer's location. The property-damage trigger excludes supplier disruption from non-physical causes including supplier financial failure, supplier labour dispute, supplier regulatory action, or supplier contract dispute.

The 2026 placement practice for supplier-concentrated buyers includes negotiation of expanded CBI trigger language to address non-physical disruption causes. The expanded triggers (sometimes called wide-form CBI or supply chain insurance) provide broader cover but at higher pricing and selective capacity. The placement decision depends on the specific exposure pattern and the buyer's risk transfer priorities.

CBI deductibles and the supplier interruption threshold

CBI deductibles typically operate as time-element deductibles on the supplier disruption duration. A 14-day deductible means the CBI indemnity commences when the supplier disruption has affected the buyer for 14 days, with the buyer absorbing the first 14 days of impact. The deductible structure recognises that short supplier disruptions are absorbed by the buyer's inventory and operational flexibility, with CBI targeted at extended disruption.

Supplier financial-health monitoring is the discipline that detects supplier distress before it becomes operational disruption. The 2026 practice has moved beyond traditional credit reports toward active intelligence covering financial indicators, operational signals, and external developments.

Traditional credit reports

Credit reports from Dun and Bradstreet, CRISIL, ICRA, India Ratings, CARE, and similar agencies provide structured financial assessments of suppliers including financial ratio analysis, payment performance, public credit ratings (for rated entities), and litigation and regulatory history. Credit reports are the foundation of supplier financial monitoring but provide a point-in-time view with limited forward signal.

Active financial intelligence

Active financial intelligence supplements credit reports with continuous monitoring of supplier-side signals. The signals include the following.

1. Payment behaviour to other parties: indications from credit bureaus and trade information networks about the supplier's payment performance across its broader customer base.
2. Banking and financial relationships: changes in the supplier's banking arrangements, working capital facility utilisation, or credit availability.
3. Capital structure changes: equity raises, debt restructuring, ownership changes, or related-party transactions that may signal distress.
4. Regulatory and tax filings: filings of statutory returns (GST, income tax, ROC) that signal operational continuity, with missed filings flagging potential distress.
5. Insolvency and litigation filings: filings at NCLT, civil courts, or arbitration tribunals affecting the supplier.

Operational signals

Operational signals from the supplier relationship provide additional monitoring inputs.

1. Order acceptance behaviour: supplier hesitation on new orders, requests for prepayment, or volume capacity limitations signalling underlying issues.
2. Delivery performance: deteriorating delivery on-time performance, quality issues, or capacity constraints affecting the buyer's supply.
3. Workforce indicators: supplier-side layoffs, key personnel departures, or labour disputes.
4. Site visits and audits: information from the buyer's procurement and quality teams during routine supplier interaction.

External developments

External developments affecting the supplier provide further monitoring inputs.

1. Industry sector dynamics: pressure on the supplier's industry affecting its broader viability.
2. Customer concentration risk on the supplier side: the supplier's own customer concentration creating vulnerability if a major customer of the supplier reduces or terminates business.
3. Geopolitical developments: trade policy changes, sanctions, or political instability affecting suppliers in specific geographies.
4. Weather and natural events: monsoon, cyclone, earthquake, or other natural events affecting the supplier's operations or its own supply chain.

The supplier monitoring operating model

For Indian mid-market corporates with 50 to 200 critical suppliers, the practical monitoring operating model includes the following.

1. Tiered monitoring intensity: Tier-1 critical suppliers monitored continuously through automated tools and quarterly structured review; Tier-2 important suppliers monitored quarterly through credit reports and operational signals; Tier-3 standard suppliers monitored annually through credit reports.
2. Dedicated supplier risk team: typically 2 to 8 analysts depending on supplier base size, often within the procurement or supply chain function with dotted-line reporting to the risk function.
3. Integration with risk register: material supplier risks identified through monitoring should be reflected in the enterprise risk register with appropriate residual scoring.
4. Escalation protocols: structured escalation for supplier risk events through procurement, supply chain, risk, and finance functions with defined response actions.
5. Annual independent review: annual external review of the monitoring process and the supplier risk register, typically by the audit or risk consultant.

Investment scale

The investment scale for supplier financial-health monitoring varies by company size. Mid-market corporates typically invest INR 30 to 80 lakh annually including tools, data subscriptions, and team capacity. Large-cap corporates with extensive supplier bases typically invest INR 1 to 5 crore annually. The investment is modest relative to the disruption cost that the monitoring is designed to prevent.

Dual-sourcing is the structural mitigation that reduces the consequences of supplier disruption. The 2020 to 2026 period has seen Indian corporates progressively expand dual-sourcing in critical categories, with the economic calculation shifting in favour of dual-sourcing as the disruption cost recognition has increased.

The dual-sourcing economic calculation

The traditional procurement economic calculation favoured concentration in fewer suppliers because of volume discount, relationship investment, and operational simplicity. The post-2020 recalculation incorporates the disruption cost into the economic comparison, with the calculation now typically running as follows.

1. Single-source baseline: lower unit cost, simpler operations, higher disruption risk.
2. Dual-source alternative: modestly higher unit cost (typically 2 to 8 percent), higher operational complexity, materially lower disruption risk.
3. Multi-source alternative: further unit cost increase, higher complexity, lowest disruption risk.

The economic optimal point shifts toward dual-sourcing or multi-sourcing when the disruption cost (estimated through scenario analysis of single-source failure events) is included in the calculation. For most Indian corporates in 2026, the dual-source point is economically attractive on the highest-criticality categories even with the unit cost premium.

Alternate-supplier qualification

Dual-sourcing requires alternate suppliers to be qualified for the relevant supply category. Qualification involves multiple steps that take time and cost.

1. Supplier search and identification: identifying potential alternate suppliers with the required technical capability, capacity, and quality profile.
2. Initial assessment: financial assessment, capacity assessment, quality system review, regulatory compliance verification.
3. Sample production: production of qualification samples meeting the buyer's specifications.
4. Technical qualification: testing of samples against the buyer's quality standards.
5. Customer-side qualification: where the buyer's product is itself subject to customer qualification (automotive, pharmaceutical, aerospace), the alternate supplier must be approved by the buyer's customer.
6. Volume ramp-up: progressive volume allocation to the alternate supplier through trial production, validation production, and steady-state production.

The qualification timeline varies materially by category. Standard commodity inputs may qualify in 1 to 3 months. Specialty chemicals or specific component categories may take 6 to 12 months. Pharmaceutical APIs may take 12 to 24 months including regulatory approval. Automotive structural components or aerospace parts may take 18 to 36 months including OEM qualification.

Pre-positioned alternate suppliers

For the highest-criticality categories, the 2026 practice is to maintain pre-positioned alternate suppliers that are qualified but operating at reduced volume, with the capability to scale rapidly during primary supplier disruption. The pre-positioned model requires ongoing volume allocation to the alternate (typically 10 to 30 percent of total) to maintain the supplier relationship, technical readiness, and capacity availability.

The pre-positioned model is the economic intermediate between full dual-sourcing (50-50 allocation) and reliance on a single source with no alternate. The model is well-suited to categories where the unit cost differential between primary and alternate is significant and full dual-sourcing would be expensive.

Geographic diversification within dual-sourcing

Dual-sourcing across geographically diversified suppliers provides protection against geographic concentration risk. The China-plus-one strategy specifically targets geographic diversification, with Indian corporates progressively qualifying alternate suppliers in Vietnam, Indonesia, Thailand, the Philippines, Bangladesh, Mexico, Eastern Europe, and other geographies relative to historical China concentration.

The geographic diversification carries operational and economic costs including logistics complexity, communication and time-zone challenges, and unit cost differentials. The 2026 economic calculation typically supports geographic diversification for the highest-criticality categories with continued China concentration acceptable for lower-criticality and commodity inputs.

PLI scheme implications

The Production Linked Incentive schemes across electronics, semiconductors, pharmaceuticals, specialty chemicals, automotive components, telecom equipment, and other categories provide policy incentives for domestic production capacity expansion. The PLI implications for supplier concentration include progressively expanding domestic supplier capability in categories previously dependent on imports, with the 2026 to 2030 PLI investment cycle expected to materially reduce import concentration in selected categories.

For Indian corporates, the practical PLI engagement involves monitoring the domestic capacity additions in their input categories, qualifying domestic alternates as capacity becomes available, and adjusting the supplier portfolio toward the emerging domestic base where the technical and economic profile supports the shift.

Two specific supplier concentration exposures dominate the Indian corporate risk discussion in 2026: semiconductor supply for electronics, automotive, and industrial applications, and API import dependency for pharmaceutical manufacturing.

Semiconductor supply concentration

Indian electronics and automotive sectors face material semiconductor supply concentration with the global semiconductor industry concentrated in specific geographies (Taiwan, South Korea, China, Japan, the United States, and limited European capacity). The 2021 to 2023 semiconductor shortage demonstrated that supply disruption can halt production for extended periods across multiple sectors.

The Indian corporate exposure runs through multiple channels.

1. Direct semiconductor sourcing: companies sourcing semiconductors directly from international suppliers face the concentration directly.
2. Indirect exposure through electronic components: companies sourcing electronic components (modules, sub-assemblies) from intermediate suppliers carry indirect semiconductor exposure.
3. Equipment-side exposure: companies using semiconductor-dependent equipment (industrial control systems, instrumentation) carry exposure to equipment availability and maintenance.
4. Customer-side exposure: companies supplying semiconductor-dependent customers (automotive OEMs, electronics manufacturers) carry secondary exposure to customer disruption.

The 2026 mitigation strategies include domestic semiconductor capacity development through the India Semiconductor Mission with the Tata-PSMC fab at Dholera, the Micron facility at Sanand, the Tower Semiconductor JV plans, and the Vedanta-Foxconn restart efforts. The capacity will progressively reduce import dependence through the 2027 to 2030 horizon. In the interim, Indian corporates manage semiconductor concentration through extended inventory buffers, supplier relationship management with international suppliers, dual-sourcing across multiple international suppliers, and CBI cover for the highest-exposure customer relationships.

API import dependency

The Indian pharmaceutical industry sources approximately 60 to 70 percent of bulk API requirements from imports, with China the dominant single source. The 2022 China lockdown disruption demonstrated the strategic vulnerability of the import-dependent API supply chain.

The API concentration mitigation has multiple components.

1. PLI Scheme for Bulk Drugs: the government's PLI scheme for bulk drugs and API manufacturing supports domestic capacity development with investment of approximately INR 6,940 crore across the scheme period, targeting capacity expansion in 41 critical APIs and key starting materials.
2. Pharmaceutical industry investment: major Indian pharmaceutical companies including Aurobindo, Dr. Reddy's, Lupin, Cipla, Sun Pharma, Cadila, and others have invested in domestic API capacity expansion.
3. Multi-source API qualification: pharmaceutical companies have progressively qualified multi-source APIs reducing single-source dependency for the highest-criticality molecules.
4. Inventory buffer expansion: pharmaceutical companies maintain extended inventory buffers on critical APIs particularly for products with limited substitution flexibility.

The 2026 to 2030 trajectory for API domestic capacity is materially positive but the transition from 60 to 70 percent import dependence to a substantially lower level will take through the 2030s. The corporate-level risk management in the interim relies on monitoring, dual-sourcing, inventory buffers, and CBI cover with specific named-supplier extensions for the most critical API sources.

Cross-cutting strategic implications

The semiconductor and API concentration exposures share several strategic implications for Indian corporate risk management.

1. Multi-year mitigation horizons: the structural concentration is not resolvable in a single annual planning cycle; the mitigation requires multi-year investment, capacity development, and qualification work.
2. Government policy alignment: the PLI schemes and related policy initiatives drive the trajectory of domestic capacity development; corporate strategies that align with policy direction benefit from the capacity availability as it materialises.
3. Insurance bridge during transition: CBI cover and supply chain insurance provide financial bridge during the multi-year mitigation period, with the insurance role most material in the highest-concentration interim period.
4. Board-level reporting: the strategic nature of the exposures requires board-level engagement on the mitigation strategy, the investment commitment, and the residual risk acceptance.

Supplier audits have transformed through the 2020 to 2026 period. The traditional supplier audit focused on quality system compliance, regulatory documentation, and financial stability. The post-COVID supplier audit framework extends to operational resilience, risk management maturity, and the supplier's own supplier base.

Audit scope expansion

The post-COVID supplier audit scope expanded in five dimensions.

1. Operational resilience: the supplier's BCP, disaster recovery, alternate-site arrangements, and capacity flexibility during disruption.
2. Cybersecurity: the supplier's information security posture, particularly for suppliers with integration into the buyer's systems or with access to the buyer's data under DPDP Act 2023 requirements.
3. Sub-tier supply chain: the supplier's own supplier base, sub-tier concentration, and the supplier's ability to manage its own supply chain risks.
4. Financial resilience: extended financial assessment including stress scenarios, working capital flexibility, and access to financing during disruption.
5. ESG and sustainability: the supplier's environmental practices, labour practices, governance maturity, and alignment with the buyer's BRSR commitments.

Audit cadence and tiering

The audit cadence in 2026 typically uses tiered intensity matched to supplier criticality.

1. Tier-1 critical suppliers: annual on-site audit covering full scope, supplemented by quarterly virtual review and continuous monitoring.
2. Tier-2 important suppliers: biennial on-site audit, annual virtual review.
3. Tier-3 standard suppliers: triennial on-site audit (or self-certification for the smallest), annual virtual confirmation.
4. Specific event triggers: out-of-cycle audits triggered by supplier-side events (changes in ownership, material incidents, financial distress signals).

Audit execution capacity

Audit execution capacity for Indian corporates with 50 to 200 critical suppliers typically requires 4 to 12 audit professionals in the supplier audit function, with the function reporting to procurement, supply chain, or quality. The function is often supplemented by third-party audit firms (Bureau Veritas, SGS, TUV SUD, Intertek, Lloyd's Register, and specialist Indian audit firms) for site visits at distant or international suppliers.

The annual audit cost for a mid-market corporate with 80 to 120 critical suppliers typically runs INR 1.5 to 4 crore including internal team cost, third-party audit fees, and travel and logistics. Large-cap corporates with extensive supplier bases typically invest INR 8 to 25 crore annually on supplier audits.

Audit outputs and follow-up discipline

Audit outputs include the audit report, the supplier risk score, the identified gaps and improvement actions, and the timeline for closure. The follow-up discipline is the critical operating practice that converts audit findings into actual risk reduction.

1. Action tracking: structured tracking of identified actions through to closure with defined ownership, deadlines, and verification.
2. Re-audit on closure: verification audit confirming that material gaps have been closed before closing the action.
3. Supplier scorecard integration: supplier audit findings integrated into the overall supplier scorecard affecting procurement allocation, payment terms, and renewal decisions.
4. Risk register integration: material supplier risks identified through audit reflected in the enterprise risk register with appropriate treatment.
5. Escalation for non-closure: structured escalation for suppliers failing to close material findings, potentially leading to supplier disqualification or volume reallocation.

The integration of supplier audit with insurance and BCP

The supplier audit framework should integrate with the CBI insurance placement and the BCP design. The integration points include the following.

1. Audit outputs as CBI placement input: the audit assessment of the supplier supports the insurer's underwriting of named-supplier extensions, with strong audit outputs supporting better placement terms.
2. Audit-identified risks as BCP triggers: material audit findings that the supplier has not closed should drive elevated BCP scenario planning for that supplier dependency.
3. Insurance treatment in audit scope: the audit should review the supplier's own insurance coverage particularly for the property and BI cover at the supplier's location.
4. Joint exercises with critical suppliers: BCP exercises with critical suppliers (similar to vendor cyber tabletop exercises) test the disruption response coordination beyond the static audit framework.

For brokers engaging with Indian corporates on supplier concentration risk in 2026, the practical positioning is to support the integration between supplier audit, BCP, and CBI cover rather than treating each as separate placement conversation. The corporates that operate the integrated framework experience materially better outcomes on supplier disruption events than the corporates that operate each component independently. The 2026 commercial broker market increasingly differentiates on this integrated capability, with leading brokers building specialist supply chain risk practices that bridge the procurement, risk, and insurance functions for their clients.